Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cancer Biol Ther. 2020;21(1):17-25. doi: 10.1080/15384047.2019.1647050. Epub 2019 Oct 8.
Gastric cancer (GC) is the second most prevalent carcinoma resulting in cancer-related deaths in the world, with differences among geographic areas. Although the incidence and mortality rates of GC in Asia are decreasing, the search for diverse and effective therapies of GC is still needed to be fully inquired. The present research explored the expression pattern, functional role and underlying mechanism of DLX6-AS1 in GC. Firstly, we measured DLX6-AS1 expression in GC and then found the elevated level of DLX6-AS1. To further inspect the function role of DLX6-AS1 involved in GC, we performed lost-of-function assays. The silencing of DLX6-AS1 suppressed cell proliferation, migration and EMT process of GC cells. Subsequently, we uncovered that MAP4K1 was also up-regulated in GC and could be positively regulated by DLX6-AS1. Moreover, MAP4K1 down-regulation similarly inhibited GC progression. In addition, DLX6-AS1 stabilized MAP4K1 via modulating FUS. In summary, DLX6-AS1 modulated GC progression through FUS-regulated MAP4K1. Our paper exposed the role and regulatory mechanism of DLX6-AS1 in GC, which suggested a novel and valid therapy for GC patients.
胃癌（GC）是导致全球癌症相关死亡的第二大常见癌种，其在地理区域间存在差异。尽管亚洲地区 GC 的发病率和死亡率呈下降趋势，但仍需要探索更多有效的 GC 治疗方法。本研究旨在探讨 DLX6-AS1 在 GC 中的表达模式、功能作用和潜在机制。首先，我们测量了 GC 中 DLX6-AS1 的表达水平，发现其表达水平升高。为了进一步研究 DLX6-AS1 在 GC 中涉及的功能作用，我们进行了功能丧失实验。DLX6-AS1 的沉默抑制了 GC 细胞的增殖、迁移和 EMT 过程。随后，我们发现 MAP4K1 在 GC 中也被上调，并可被 DLX6-AS1 正向调控。此外，MAP4K1 的下调也同样抑制了 GC 的进展。此外，DLX6-AS1 通过调节 FUS 来稳定 MAP4K1。综上所述，DLX6-AS1 通过 FUS 调节的 MAP4K1 来调节 GC 的进展。我们的论文揭示了 DLX6-AS1 在 GC 中的作用和调控机制，为 GC 患者提供了一种新的有效治疗方法。
